— GINECO —

Présentations du GINECO à l'ASCO 2018

Par le biais de cette page, vous pouvez accéder à l'ensemble des présentations du GINECO à l'ASCO (American Society of Clinical Oncology).

 

Le GINECO à l'ASCO 2018

 

Page d'accès aux présentations du GINECO au congrès de l'ASCO qui s'est tenu du 1er au 5 juin 2018


Le GINECO était, cette année encore, très présent à l'ASCO.

Session orale gynéco :

  • MITO 16
    Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.

Session poster discussion :

  • AGO-OVAR16
    Survie globale
    AGO-OVAR 16
    A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results.

Session poster :

  • SOLO2
    Incidence of Myelodisplastic syndrome and Acute leukemia
    Olaparib did not increase the risk of MDS/AML vs placebo in SOLO2
  • Gannet 53
    Résultats phase I-II
  • Vivrovaire
    Résultats severe chronic fatigue
    Depression, persistence of neurotoxicity, and sleep disturbance are the main determinants of Severe Chronic Fatigue among Ovarian Cancer Survivors. These symptoms should be early detected and treated.
  • SOLO2
    incidence of Myelodisplastic syndrome and Acute leukemia
    Olaparib did not increase the risk of MDS/AML vs placebo in SOLO2
  • Gannet 53
    Résultats phase I-II
  • Vivrovaire
    Résultats severe chronic fatigue
    Depression, persistence of neurotoxicity, and sleep disturbance are the main determinants of Severe Chronic Fatigue among Ovarian Cancer Survivors. These symptoms should be early detected and treated.
  • Megadatabase GCIG :
    Progression free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line advanced ovarian cancer (AOC) therapy: A Gynecologic Cancer InterGroup individual (GCIG) patient-level (IPD) analysis of multiple randomized trials.
    8,973 patients enrolled in 15 randomized first line trials
    This large IPD meta-analysis did not establish PFS as a surrogate endpoint for OS in first line treatment of AOC
  • Réunions
    • Study in progress : Atalante , SENTICOLIII
    • TSC PAOLA
    • TSC Atalante
    • TSC OREO
    • Réunion SOLO2 substudies
    • TSC First
    • TSC AGO2.29
    • TSC DUO-O
    • les études AGO 2.21, Corail qui devaient être présentées à ASCO le seront à ESMO
    • Alienor
    • Monavi RT
    • SOLO2 (long term tolerability)
    • Study in progress : First

 

Haut de page

Modifié le 05-12-2018 12:12